Merck Frosst v. Apotex over enalapril
Executive Summary
Ottawa federal court rules Dec. 14 that Apotex' generic version of the heart drug, Apo-enalapril, infringes Merck's product patent on the innovator drug Vasotec, Merck Frosst reports. Judge Andrew MacKay found that Merck Frosst is entitled to: a permanent injunction restraining Apotex from selling its product, an order for delivery up or destruction of Apo-enalapril products, and damages or an accounting of Apotex' profits. Apotex says the judge did not enjoin the firm and that it is appealing his infringement decision. On Dec. 15, Canada's Supreme Court upheld the Health Protection Branch's issuance of a notice of compliance to Apotex for Apo-enalapril. Merck had challenged the notice of compliance
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth